METHOD OF TREATING WET AGE-RELATED MACULAR DEGENERATION OF RETINA WITH USING CELL TRANSPLANTATION Russian patent published in 2012 - IPC A61F9/00 A61K35/28 A61K38/17 A61K38/45 A61K39/395 A61P27/02 A61N5/67 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely ophthalmology, and concerns treating wet age-related macular degeneration (AMD). That is ensured by the injections of Lucentis 0.5 mg once a month into vitreous body. It is followed by the parabulbar introduction of alpha-fetoprotein 0.0075 mg in the evening and glutathione-S-transferase 0.0000005 g in the morning in isotonic solution 1.5 ml. The introduction is performed into each eye daily to visualise retina with neovasculature surrounding macula. Then laser vascular coagulation follows without macula damaging. A suspension of autologous bone marrow mononuclears are transplanted parabulbarly and retrobulbarly close to macula. Mononuclear count makes 5-40 mln. The suspension is introduced in NCTF-135 1.5 ml. The introduction is performed 2-4 times every 2 months.

EFFECT: method enables arresting neoangiogenesis, relieving autoimmune process within ocular tissues, ie lead to blocking pathogenetic mechanisms of developing AMD that eliminates recurrence of the disease with creating the conditions for organotypic regeneration of retina and evident improvement of visual function.

1 ex